Ved afslutningen af den intravenøse behandling havde 96 (76%) af de 127 patienter, som fik ECALTA, responderet på behandlingen, mod 71 (60%) af de 118, som fik fluconazol.
At the end of intravenous therapy, 96 (76%) of the 127 patients receiving ECALTA had responded to treatment, compared with 71 (60%) of the 118 receiving fluconazole.